A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerative colitis.

• Conditions: Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) =5 and SCCAI subscore for blood in stool” =2 at Baseline Visit.; MedDRA version: 12.0Level: LLTClassification code 10045365Term: Ulcerative colitis

• Registration Number: EUCTR2008-007952-90-LT
• Lead Sponsor: ipid Therapeutics GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-09-15
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

1) Men and women =18 years who have given written Informed Consent,
2) Patients with proven UC (according to ECCO consensus definition [28]:
UC is a chronic continuous mucosal inflammation of the colon without
granulomas on biopsy, affecting the rectum and variable extent of the colon
in continuity, which is characterized by a relapsing and remitting course. The
diagnoses should be established by a combination of medical history, clinical
evalution, and typical endoscopic and histologic findings:
a) Medical history and clinical features: loose stools [>6 weeks], episodes of
bloody stools and stool urgency, episodes of relapse and periods of
remission or an unremitting, continuous course over months; exclusion of
infectious colitis [microbiological testing, including Clostridium difficile toxin A
and B, Campylobacter spp., E. coli 0157:H7; depending on the medical
history fresh, warm stool samples should be tested for amoebae or other
parasites], exclusion of drug-induced forms of colitis,
b) Endoscopic features, including a colonoscopy with intubation of the
terminal ileum: inflammation of the rectum, continuous inflammation to more
proximal parts, usually clear demarcation between inflamed and normal
areas. Signs of inflammation are vascular congestion or reduction of visible
vascular patterns, as well as mucosal friability [after contact with the
endoscope]. Moreover, a coarse granular appearance, mucosal erosions or
ulcerations may occur,
c) Histologic features from multiple mucosal biopsies: absence of
granulomas, architectural features [crypt branching, crypt distortion, crypt
atrophy or surface irregularity], epithelial cell abnormalities [mucin depletion,
Paneth cell metaplasia] and inflammatory signs [increased lamina propria
cellularity, basal plasmacytosis, basal lymphoid aggregates, lamina propria
eosinophils],
Patients may be included into the study if clinician, endoscopist [may be
identical with clinician] and pathologist state that the found features are
compatible with the diagnosis of UC),
3) Patients naïve to any form of controlled release PC treatment,
4) Active disease course for the last 6 weeks or longer with bloody diarrhea
(anamnestic mean number of bloody stool per day =4),
5) SCCAI =5 and SCCAI subscore for blood in stool” =2 at Baseline Visit (V2),
(SCCAI and subscore for blood are calculated as the rounded mean over the
last 7 days),
6) Patients with an inadequate response to a treatment with =3g of mesalazine
per day, over a period of 4 weeks or a documented intolerance to
mesalazine,
7) Other drugs for the treatment of UC are allowed, under the following
circumstances:
- Systemic acting oral steroids are allowed if taken for =8 weeks prior to start
of the study with a stable dose for =4 weeks prior to start of the study,
- Immunosuppressive therapy with azathioprine (2-2.5 mg/kg) or 6-
mercaptopurine (1-1.5 mg/kg) is allowed, if taken for =3 months prior to
start of the study,
8) Ability of the patient to understand character and individual consequences of
the clinical study,
9) Special requirements for women of childbearing potential:
- Negative pregnancy test at V1 and V2,
- Use of one highly effective method of contraception for the entire duration

Exclusion Criteria

1) Toxic megacolon or fulminant colitis,
2) No current treatment for UC with either highdose 5-ASA (at least 3g/d) or oral steroids or immunosuppressants or combinations
3) Concomitant therapy as following:
a) Therapy with cyclosporine, tacrolimus, methotrexate, or tumor necrosis-
(TNF)-alpha-antagonists within 3 months prior to study entry,
b) Current treatment with opiates or loperamide,
c) Current antibiotic treatment,
4) Rectal applications of aminosalicylates, budesonide, or other steroids within
4 weeks prior to study entry,
5) Oral application of topically acting steroids, e.g. budesonide, within 4 weeks
prior to study start,
6) Treatment with other IMP within 3 months prior to study entry,
7) Condition after complete or partial resection of the colon,
8) Infectious colitis, including cytomegalovirus or Clostridium difficile induced
colitis,
9) Crohn’s disease,
10) Colitis due to other reasons than UC like known diverticulitis, radiation colitis,
ischemic colitis, microscopic colitis, or indeterminate colitis,
11) Malabsorption syndromes, chronic pancreatitis,
12) Celiac disease,
13) Acute bleeding hemorrhoids,
14) Other inflammatory or bleeding disorders of the gastrointestinal tract, or
diseases that may cause diarrhea or gastrointestinal bleeding,
15) Pregnant or nursing women,
16) Known drug, alcohol, or medication abuse during the last 2 years prior to
start of the study,
17) Any other uncontrolled systemic diseases (e.g. cardiac, renal, pulmonary, or
hepatic) or severe chronic diseases (e.g. malignant tumor, HIV infection,
high-grade intraepithelial neoplasia),
18) Ulcerative proctitis with a disease extent <10 cm,
19) Participation in another clinical trial within the last 30 days, simultaneous
participation in another clinical trial, or previous participation in this trial.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The primary objective of this study is to assess the efficacy and safety of modified-release PC (LT-02) in mesalazine-refractory UC.;Secondary Objective: The secondary objective is to determine the optimal dose of modified-release PC<br>(LT-02) in mesalazine-refractory UC.;Primary end point(s): Mean rounded SCCAI change from baseline (V2) to Week 12 (V5) or last assessment during the double-blind treatment period.